Please assess the completion status of the following clinical trial:

Trial Title: Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Signed ICF (Informed Consent Form)~* Subject-reported history of Drye Eye Disease (DED) in both eyes~* Ability and willingness to follow instructions, including participation in all study assessments and visits~Exclusion Criteria:~* Women who are pregnant, nursing or planning pregnancy~* Unwillingness to submit a blood pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control~* Clinically significant slit-lamp findings or abnormal lid anatomy at screening~* Ocular/peri-ocular malignancy~* History of herpetic keratitis~* Active ocular allergies or ocular allergies that are expected to be active during the study~* Ongoing ocular or systemic infection~* Wear contact lenses within 1 month prior to screening or anticipated use of contact lenses during the study~* Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have planned ocular and/or lid surgeries over the study period~* Presence of uncontrolled systemic diseases~* Presence of known allergy and/or sensitivity to the study drug or saline components~* Use of any topical steroids treatments, topical cyclosporine, lifitegrast, serum tears or topical anti-glaucoma medication within 2 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NOV03 4 times daily (QID) (Type: EXPERIMENTAL): Perfluorohexyloctance solution 4 times daily (QID)
- NOV03 2 times daily (BID) (Type: EXPERIMENTAL): Perfluorohexyloctance solution 2 times daily (BID)
- Placebo 4 times daily (QID) (Type: PLACEBO_COMPARATOR): Saline solution (0.9% sodium chloride solution) 4 times daily (QID)
- Placebo 2 times daily (BID) (Type: PLACEBO_COMPARATOR): Saline solution (0.9% sodium chloride solution) 2 times daily (BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).